(Q30680317)

15 August 2017

1 reference

14 September 2020

ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data (English)

1 reference

15 August 2017

1 reference

14 September 2020

1 reference

17 November 2019

1 reference

17 November 2019

1 reference

14 September 2020

J F Robertson

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2001

8 references

British Journal of Cancer

15 August 2017

13 March 2019

3 April 2019

18 June 2019

17 June 2019

13 November 2019

17 November 2019

14 September 2020

8 references

15 August 2017

13 March 2019

3 April 2019

18 June 2019

17 June 2019

13 November 2019

17 November 2019

14 September 2020

85 Suppl 2

1 reference

15 August 2017

11-14

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375169

15 August 2017

1 reference

Gynecologic effects of tamoxifen and the association with endometrial carcinoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375169

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375169

Use of pure antioestrogens to elucidate the mode of action of oestrogens

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375169

A potent specific pure antiestrogen with clinical potential

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375169

Tamoxifen flare in advanced breast cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375169

Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375169

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375169

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth

25 November 2018

1 reference

12 December 2020

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

1 reference

12 December 2020

ICI 182,780: a pure antiestrogen that affects behaviors and energy balance in rats without acting in the brain

1 reference

12 December 2020

ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen

1 reference

12 December 2020

Identifiers

1 reference

15 August 2017

PubMed publication ID

11900210

1 reference